ClinicalTrials.gg
CompletedNCT00998192Updated Mar 31, 2016

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

A Phase 2 interventional study of REOLYSIN and Paclitaxel in Metastatic or Recurrent Squamous Cell Carcinoma of the Lung, sponsored by Oncolytics Biotech. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-31.

Sponsored by Oncolytics Biotech · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing paclitaxel in Neoplasm Metastasis — 7 open to participants now, 12 under way, 2 of them phase 3. Paclitaxel · Neoplasm Metastasis.

Enrollment
44th of 63
32 · median 43
Started
2009
with 4 others
Phase 2
41 of 64
5 open now
Registered
24th of 64
by date
Lead sponsor
2 of 64
Oncolytics Biotech

Among the 64 studies testing paclitaxel in Neoplasm Metastasis, this one is the 44th largest by enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2009, is one of 41 in phase 2, and was the 24th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

7 of the 64 studies testing paclitaxel in Neoplasm Metastasis are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing paclitaxel in Neoplasm Metastasis, or all of them as a file.
02

Study summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.

Read the detailed description

Lung cancer remains the most common cancer and cause of cancer-related mortality in the United States. In 2008, there was an estimated 215,000 new cases of lung cancer diagnosed and roughly 162,000 deaths from lung cancer (NCI 2009). The majority (85%) of patients with a diagnosis of lung cancer will have non-small cell lung cancer (NSCLC).

The combination of paclitaxel and carboplatin has become the most commonly prescribed chemotherapy regimen for the treatment of advanced NSCLC in the United States. Laboratory studies of combinations of REOLYSIN with a variety of chemotherapeutic agents has shown that the combination of REOLYSIN and paclitaxel was invariably synergistic, even in cells with drug resistance or limited sensitivity to the reovirus. Moreover, reovirus activity was dramatically increased in the presence of the taxane.

The Phase 2 study is designed to characterize the efficacy and safety of REOLYSIN given intravenously in combination with paclitaxel and carboplatin every 3 weeks in patients with squamous cell carinoma of the lung.

Response is a primary endpoint of this trial.

The safety of the treatment combination will be assessed by the evaluation of the type, frequency and severity of adverse events, changes in clinical laboratory tests, immunogenicity and physical examination.

Patients may continue to receive chemotherapy combined with REOLYSIN for up to 8 cycles and may continue indefinitely on REOLYSIN monotherapy under this protocol, provided they have not experienced either progressive disease or unacceptable drug-related toxicity that does not respond to either supportive care or dose reduction.

03

Conditions studied

  • Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

Keywords

  • carcinoma
  • squamous cell
  • lung
  • REOLYSIN
  • chemotherapy
  • carboplatin
  • paclitaxel
  • Carcinoma, Squamous Cell of the Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have or cytologically confirmed stage IIIB (pleural effusion; IVA on revised IASLC staging) or stage IV, or recurrent squamous cell carcinoma of the lung.
  • have .
  • be chemotherapy naïve for their metastatic or recurrent SCCLC, with some exceptions.
  • have NO continuing acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures.
  • have an Performance Score of ≤ 2.
  • have a of at least 3 months.
  • (ANC) ≥ 1.5 x 10\^9; ≥ 100 x10\^9 (without platelet transfusion); ≥ 9.0 g/dL (with or without RBC transfusion); Serum creatinine ≤ 1.5 x (ULN); ≤ 1.5 x ULN; /ALT ≤ 2.5 x ULN.
  • negative pregnancy test for females with .

Exclusion criteria

Exclusion Criteria:

  • receive concurrent therapy with any other anticancer agent while on study.
  • have a known past or current history of (es).
  • be on therapy or have known infection or active or C.
  • be a pregnant or breast-feeding woman.
  • have cardiac disease.
  • have dementia or altered mental status that would prohibit .
  • have any other acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the patient inappropriate for this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Interventions

  • BiologicalREOLYSIN

    3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle

  • 200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle

    Also known as: Taxol

  • 6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle

    Also known as: Paraplatin

06

What researchers measure

Primary outcomes

  1. Objective response rate (complete response (CR) + partial response (PR)) of the treatment regimen in the study population

    Time frame: 6 months

Secondary outcomes

  1. Evaluate the safety and tolerability of the treatment regimen in the study population as measured by adverse events associated with the study treatment, and defined by established criteria.

    Time frame: Within 30 days of last dose of REOLYSIN

  2. To assess progression-free survival (PFS) for the treatment regimen in the study population.

    Time frame: 9-12 months

  3. Determine the proportion of patients receiving the treatment who are alive and free of disease progression at 6 months.

    Time frame: 6 months

  4. To determine overall survival with the treatment regimen in the study population

    Time frame: 9-12 months

07

Study locations

17 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Ocala Oncology Center
    Ocala, Florida 34471, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Investigative Clinical Research of Indiana, LLC
    Indianapolis, Indiana 46260, United States
  • Advanced Oncology Associates
    Armonk, New York 10504, United States
  • Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042, United States
  • Medical Oncology Associates of Wyoming Valley
    Kingston, Pennsylvania 18704, United States
  • Texas Oncology - Arlington South
    Arlington, Texas 76014, United States
  • Texas Oncology - Bedford
    Bedford, Texas 76022, United States
  • Texas Oncology - Denton South
    Denton, Texas 76210, United States
  • Texas Oncology - Fort Worth
    Fort Worth, Texas 76104, United States
  • Texas Oncology - Garland
    Garland, Texas 75042, United States
  • Texas Oncology - Lewisville
    Lewisville, Texas 75067, United States
  • Cancer Therapy & Research Center at UTHSCSA
    San Antonio, Texas 78229, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78258-3912, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Lynchburg Hematology Oncology Clinic
    Lynchburg, Virginia 24501, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Sep 2013 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2009
First posted
Oct 20, 2009
Start
Oct 2009
Primary completionActual
Sep 2013
CompletionActual
Aug 2015
Last update
Mar 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00998192
Lead sponsor
Oncolytics Biotech
Collaborators
University of Texas
Responsible party
Sponsor
First posted
Oct 20, 2009
Start date
Oct 2009
Primary completion
Sep 2013
Completion
Aug 2015
Last update
Mar 31, 2016

Study contacts

Alain Mita, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pelareorep · Paclitaxel · Carboplatin

Start the discussion